Investigation of the Effects of Virtual Reality Applications on Individuals Diagnosed With Schizophrenia

NCT ID: NCT07027085

Last Updated: 2025-06-18

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 52 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-06-02
• Study Completion Date: 2025-12-31

Brief Summary

Despite all the positive facts about the use of virtual reality technology in the assessment and treatment of schizophrenia, there are few publications per year. There are few controlled studies covering the effectiveness of virtual reality programs in the training of cognitive and social skills. In future research, more randomized studies with more robust samples are expected, because the results of experimental studies so far encourage this new treatment approach. Therefore, the aim of this study is to examine the effects of virtual reality application on sensory, social and cognitive areas in individuals with schizophrenia.

Detailed Description

Schizophrenia is a chronic disease that can cause serious disability and negatively affect quality of life and functionality. According to the results of studies conducted to date, it is assumed that schizophrenia is a syndrome rather than a single disease due to its different clinical types, clinical appearance, course and treatment responses that vary from patient to patient. Schizophrenia is one of the diseases that cause the most disability worldwide. According to World Health Organization data, schizophrenia is in the top ten list of diseases that cause disability for individuals aged 15-44. Individuals diagnosed with schizophrenia usually experience difficulties in the areas of Sensory Processing, Cognitive Functions and Social Skills. Sensory processing disorders in individuals with schizophrenia affect the processes of perceiving and interpreting environmental stimuli: Sounds, lights or tactile stimuli that are considered ordinary in daily life may become disturbing or there may be difficulty in combining visual and auditory information in a harmonious way. This situation also negatively affects social interactions. For example, Javitt and Freedman stated that sensory processing disorders in schizophrenia are related to both cognitive and social functioning dimensions of the disease.

Social skills are one of the most frequently affected areas in schizophrenia and various impairments can be observed. Difficulty in social interactions, introversion and communication problems are frequently observed. Difficulty in understanding facial expressions, body language or tone of voice, decreased ability to understand the emotional states of others or avoidance of social interactions and isolation can be observed. Pinkham et al. stated that social cognition is a significant problem in schizophrenia and that this situation has a direct effect on social functioning. Individuals with schizophrenia also experience impairments in their ability to recognize and express emotions. Kohler et al. emphasized that emotional processing disorders in schizophrenia make social relationships even more difficult.

Schizophrenia can lead to significant impairments especially in cognitive areas and this can significantly affect the individual's daily life. For example; difficulty in focusing on a sustained task, deficiencies in the ability to retain and use instant information, or impairments in higher-level cognitive functions such as problem solving, planning, and decision making. A meta-analysis found that individuals with schizophrenia had significant disadvantages compared to healthy individuals in all cognitive areas. One study showed that parietal lobe functions (related to motor planning) may be impaired in individuals with schizophrenia and that this situation has effects on motor control. These problems reduce the quality of life of individuals with schizophrenia and make it difficult for them to reintegrate into society. Innovative approaches such as virtual reality offer promising solutions for rehabilitation in these areas.

Virtual reality (VR) is a technology in which users experience the feeling of being in three-dimensional environments created by computers. This technology abstracts the user from the physical world and includes them in a virtual world through special headsets and sensors.

Virtual reality technology is used in various fields today. In recent years, it has been increasingly used in medicine and psychology. It is especially effective as a rehabilitation and treatment tool in various disease groups. Virtual reality applications have various advantages and limitations. Advantages: Individuals receive therapy in a controlled environment, away from the risks they may encounter in the real world. Virtual reality environments offer more realistic and impressive experiences than traditional therapies. Applications can be customized according to the needs of individuals. Virtual reality devices objectively measure and record the individual's behaviors and reactions. Limitations: The cost of virtual reality equipment and access to technology may be limited. Some individuals may experience side effects such as dizziness or nausea in virtual environments. More research is needed on the long-term effectiveness of some applications. Virtual reality applications in schizophrenia are drawing attention as an innovative approach to improving individuals' cognitive, social and sensory functions. Such applications provide an effective alternative to traditional methods by allowing therapeutic interventions in a safe environment. Virtual reality targets several areas where individuals with schizophrenia have difficulties. These include; Social Skills: Provides safe practice of social interactions by simulating real-life social situations.

Sensory Processing and Sensitivity: Sensory tolerance is developed by exposure to environmental stimuli.

Cognitive Rehabilitation: Provides tasks that improve attention, memory, and executive functions.

Delusion and Hallucination Management: Therapies that strengthen the perception of reality are applied.

The available data on virtual reality applications are currently limited due to the small number of studies conducted on the subject, and more research is needed to better evaluate its effectiveness as a treatment. However, current evidence reveals its effectiveness and versatility in successfully treating a variety of psychotic symptoms, including delusions, hallucinations, or cognitive and social skills, and suggests virtual reality as a promising new branch of research and therapy. The existing literature agrees on the safety, tolerability, and long-term durability of the therapeutic effects achieved with virtual reality. Studies have reported a decrease in social anxiety and an increase in self-confidence.

For example, in a randomized controlled trial by Park et al. on the use of virtual reality in the treatment of social skills, it was reported that it showed significant improvements in speaking skills and also provided greater motivation for treatment. Freeman et al. developed a virtual reality application that allowed the individual to reframe these thoughts by interacting with an avatar associated with the content of the delusion. In another study, virtual reality application was found to be effective in reducing the intensity and distress of delusions. Effective results were obtained in virtual reality applications used to improve cognitive functions. La Paglia et al. conducted virtual reality training for cognitive rehabilitation targeting attention and executive functions in patients with schizophrenia. Rus-Calafell et al. suggested that virtual reality intervention could be applied to cognitive rehabilitation, social skills training interventions and virtual reality-assisted therapies for psychosis, could provide a valuable method for assessing the presence of symptoms and has the potential to facilitate learning new emotional and behavioral responses.

Conditions

Schizophrenia Disorders

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

intervention group

Group Type: EXPERIMENTAL

virtual reality

Intervention Type: DEVICE

The intervention group will be applied 14 sessions of virtual reality application, each session lasting 30 minutes and 2 sessions per week. The sessions will be held in a room allocated for this study in the community mental health center. The device on which the application will be made was determined as Meta Quest 3. The contents to be used in the device were determined to be in line with the areas to be examined.

control group

Group Type: NO_INTERVENTION

No interventions assigned to this group

Interventions

virtual reality

The intervention group will be applied 14 sessions of virtual reality application, each session lasting 30 minutes and 2 sessions per week. The sessions will be held in a room allocated for this study in the community mental health center. The device on which the application will be made was determined as Meta Quest 3. The contents to be used in the device were determined to be in line with the areas to be examined.

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• Being diagnosed with schizophrenia
• Volunteering to participate in the study
• Being an adult between the ages of 18-65
• Not in an acute or exacerbated phase
• Scoring 19 or more on the Mini Mental State Examination

Exclusion Criteria

• Patients who have another psychological or neurological disease other than schizophrenia
• Who are unable to give their own consent will not be included in the study.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Nigde Omer Halisdemir University

OTHER

Sponsor Role: lead

Responsible Party

Fatıma Zehra Turan

Lecturer

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Niğde Ömer Halisdemir University

Niğde, , Turkey (Türkiye)

Countries

Turkey (Türkiye)

References

Erkoç Ş, Arkonaç O, Ataklı C, Özmen E. Negatif semptomları değerlendirme ölçeğinin güvenilirliği ve geçerliliği. Düşünen Adam. 1991;4(2):14-5.

Reference Type: BACKGROUND

Erkoç Ş, Arkonaç O, Ataklı C, Özmen E. Pozitif semptomları değerlendirme ölçeğinin güvenilirliği ve geçerliliği. Düşünen Adam. 1991;4(2):20-4.

Reference Type: BACKGROUND

KİRAS F, İNCEDERE A, ESEN D, GÜRCAN MB, ABUT B, İPÇİ K, et al. Şizofreni Hastaları için Toplumsal İşlevselliği Değerlendirme Ölçeğinin geliştirilmesi: Geçerlilik ve güvenirlik çalışması. Anatolian Journal of Psychiatry/Anadolu Psikiyatri Dergisi. 2018;19.

Reference Type: BACKGROUND

Gungen C, Ertan T, Eker E, Yasar R, Engin F. [Reliability and validity of the standardized Mini Mental State Examination in the diagnosis of mild dementia in Turkish population]. Turk Psikiyatri Derg. 2002 Winter;13(4):273-81. Turkish.

Reference Type: BACKGROUND

PMID: 12794644 (View on PubMed)

Özak N. Şizofreni Hastalarinda Bilişsel Bozukluk Düzeyini Değerlendiren Şizofreni Bilişsel Değerlendirme Ölçeğinin Türkçe Geçerlilik ve Güvenilirlik Çalişmasi: Dokuz Eylul Universitesi (Turkey); 2019.

Reference Type: BACKGROUND

Aydın MŞ. Adolesan/Yetişkin Duyu Profili anketi türkçe uyarlamasının geçerlilik güvenilirlik çalışması. 2015.

Reference Type: BACKGROUND

Rus-Calafell M, Garety P, Sason E, Craig TJK, Valmaggia LR. Virtual reality in the assessment and treatment of psychosis: a systematic review of its utility, acceptability and effectiveness. Psychol Med. 2018 Feb;48(3):362-391. doi: 10.1017/S0033291717001945. Epub 2017 Jul 24.

Reference Type: BACKGROUND

PMID: 28735593 (View on PubMed)

La Paglia F, La Cascia C, Rizzo R, Sanna M, Cangialosi F, Sideli L, et al. Virtual Reality environments to rehabilitation attention deficits in schizophrenic patients. Annual Review of CyberTherapy and Telemedicine. 2016.

Reference Type: BACKGROUND

Craig TK, Rus-Calafell M, Ward T, Leff JP, Huckvale M, Howarth E, Emsley R, Garety PA. AVATAR therapy for auditory verbal hallucinations in people with psychosis: a single-blind, randomised controlled trial. Lancet Psychiatry. 2018 Jan;5(1):31-40. doi: 10.1016/S2215-0366(17)30427-3. Epub 2017 Nov 23.

Reference Type: BACKGROUND

PMID: 29175276 (View on PubMed)

Freeman D, Bradley J, Antley A, Bourke E, DeWeever N, Evans N, Cernis E, Sheaves B, Waite F, Dunn G, Slater M, Clark DM. Virtual reality in the treatment of persecutory delusions: randomised controlled experimental study testing how to reduce delusional conviction. Br J Psychiatry. 2016 Jul;209(1):62-7. doi: 10.1192/bjp.bp.115.176438. Epub 2016 May 5.

Reference Type: BACKGROUND

PMID: 27151071 (View on PubMed)

Park MJ, Kim DJ, Lee U, Na EJ, Jeon HJ. A Literature Overview of Virtual Reality (VR) in Treatment of Psychiatric Disorders: Recent Advances and Limitations. Front Psychiatry. 2019 Jul 19;10:505. doi: 10.3389/fpsyt.2019.00505. eCollection 2019.

Reference Type: BACKGROUND

PMID: 31379623 (View on PubMed)

Macedo M, Marques A, Queirós C. Virtual reality in assessment and treatment of schizophrenia: a systematic review. Jornal brasileiro de psiquiatria. 2015;64(1):70-81.

Reference Type: BACKGROUND

Bisso E, Signorelli MS, Milazzo M, Maglia M, Polosa R, Aguglia E, Caponnetto P. Immersive Virtual Reality Applications in Schizophrenia Spectrum Therapy: A Systematic Review. Int J Environ Res Public Health. 2020 Aug 22;17(17):6111. doi: 10.3390/ijerph17176111.

Reference Type: BACKGROUND

PMID: 32842579 (View on PubMed)

Freeman D. Studying and treating schizophrenia using virtual reality: a new paradigm. Schizophr Bull. 2008 Jul;34(4):605-10. doi: 10.1093/schbul/sbn020. Epub 2008 Mar 28.

Reference Type: BACKGROUND

PMID: 18375568 (View on PubMed)

Ertürk NB, Değirmenci FN. SANAL GERÇEKLİK (VR) TEKNOLOJİLERİNİN MİMARLIK SEKTÖRÜNDEKİ YERİ. Karesi Journal of Architecture.2(2):24-36.

Reference Type: BACKGROUND

Bachofner H, Scherer KA, Vanbellingen T, Bohlhalter S, Stegmayer K, Walther S. Validation of the Apraxia Screen TULIA (AST) in Schizophrenia. Neuropsychobiology. 2022;81(4):311-321. doi: 10.1159/000523778. Epub 2022 Apr 1.

Reference Type: BACKGROUND

PMID: 35367989 (View on PubMed)

Nuechterlein KH, Barch DM, Gold JM, Goldberg TE, Green MF, Heaton RK. Identification of separable cognitive factors in schizophrenia. Schizophr Res. 2004 Dec 15;72(1):29-39. doi: 10.1016/j.schres.2004.09.007.

Reference Type: BACKGROUND

PMID: 15531405 (View on PubMed)

Mesholam-Gately RI, Giuliano AJ, Goff KP, Faraone SV, Seidman LJ. Neurocognition in first-episode schizophrenia: a meta-analytic review. Neuropsychology. 2009 May;23(3):315-36. doi: 10.1037/a0014708.

Reference Type: BACKGROUND

PMID: 19413446 (View on PubMed)

La Paglia F, La Cascia C, Rizzo R, Sideli L, Francomano A, La Barbera D. Cognitive rehabilitation of schizophrenia through NeuroVr training. Stud Health Technol Inform. 2013;191:158-62.

Reference Type: BACKGROUND

PMID: 23792865 (View on PubMed)

Kohler CG, Walker JB, Martin EA, Healey KM, Moberg PJ. Facial emotion perception in schizophrenia: a meta-analytic review. Schizophr Bull. 2010 Sep;36(5):1009-19. doi: 10.1093/schbul/sbn192. Epub 2009 Mar 27.

Reference Type: BACKGROUND

PMID: 19329561 (View on PubMed)

Pinkham AE, Penn DL, Green MF, Buck B, Healey K, Harvey PD. The social cognition psychometric evaluation study: results of the expert survey and RAND panel. Schizophr Bull. 2014 Jul;40(4):813-23. doi: 10.1093/schbul/sbt081. Epub 2013 May 31.

Reference Type: BACKGROUND

PMID: 23728248 (View on PubMed)

Javitt DC, Freedman R. Sensory processing dysfunction in the personal experience and neuronal machinery of schizophrenia. Am J Psychiatry. 2015 Jan;172(1):17-31. doi: 10.1176/appi.ajp.2014.13121691. Epub 2014 Nov 17.

Reference Type: BACKGROUND

PMID: 25553496 (View on PubMed)

Summakoğlu D, Ertuğrul B. Şizofreni ve tedavisi. Lectio Scientific. 2018;2(1):43-61.

Reference Type: BACKGROUND

GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016 Oct 8;388(10053):1545-1602. doi: 10.1016/S0140-6736(16)31678-6.

Reference Type: BACKGROUND

PMID: 27733282 (View on PubMed)

Uyan TT, Köroğlu A, Hocaoglu C. Şizofreni: Etiyoloji, tanı ve tedavi yaklaşımlarında güncel durum. ERÜ Sağlık Bilimleri Fakültesi Dergisi.10(1):19-35.

Reference Type: BACKGROUND

Jauhar S, Johnstone M, McKenna PJ. Schizophrenia. Lancet. 2022 Jan 29;399(10323):473-486. doi: 10.1016/S0140-6736(21)01730-X.

Reference Type: BACKGROUND

PMID: 35093231 (View on PubMed)

Other Identifiers

NiğdeOHU.OT.

Identifier Type: -

Identifier Source: org_study_id